Viewing StudyNCT03591510

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 11:44 AM
Last Modification Date: 2024-10-26 @ 12:49 PM
Study NCT ID: NCT03591510
Status: RECRUITING
Last Update Posted: 2024-04-05
First Post: 2018-06-25
Brief Title: A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Sponsor: Novartis Pharmaceuticals
Organization: Novartis
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
FLT3-mutated Acute Myeloid Leukemia
Keywords:
Name View
PKC412 View
Acute Myeloid Leukemia View
AML View
FLT3-mutated View
midostaurin View
midostaurin combined with standard chemotherapy View
single agent post-consolidation therapy View
untreated FLT3-mutated AML View
pediatric population View